ALXO - Alx Oncology Holdings  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ALXO is currently covered by 8 analysts with an average price target of $10.2. This is a potential upside of $9.76 (2218.18%) from yesterday's end of day stock price of $0.44.

Alx Oncology Holdings 's activity chart (see below) currently has 27 price targets and 62 ratings on display. The stock rating distribution of ALXO is 90% BUY and 10% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 24.21% with an average time for these price targets to be met of 74.11 days.

Highest price target for ALXO is $9, Lowest price target is $1.5, average price target is $6.45.

Most recent stock forecast was given by BRADLEY CANINO from STIFEL on 07-Mar-2025. First documented stock forecast 11-Aug-2020.

Currently out of the existing stock ratings of ALXO, 36 are a BUY (90%), 4 are a HOLD (10%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$1.5

$0.44 (41.51%)

$3

2 months 9 days ago
(07-Mar-2025)

3/7 (42.86%)

$0.44 (41.51%)

265

Buy

$5

$3.94 (371.70%)

$5

2 months 9 days ago
(07-Mar-2025)

2/8 (25%)

$3.94 (371.70%)

202

Buy

$9

$7.94 (749.06%)

$21

2 months 10 days ago
(06-Mar-2025)

4/6 (66.67%)

$7.96 (765.38%)

54

Hold

$3

$1.94 (183.02%)

$2

2 months 10 days ago
(06-Mar-2025)

1/6 (16.67%)

$1.96 (188.46%)

93

Buy

$2.2

$1.14 (107.55%)

$4

3 months 19 days ago
(27-Jan-2025)

0/5 (0%)

$0.64 (41.03%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ALXO (Alx Oncology Holdings ) average time for price targets to be met?

On average it took 74.11 days on average for the stock forecasts to be realized with a an average price target met ratio 24.21

Which analyst has the current highest performing score on ALXO (Alx Oncology Holdings ) with a proven track record?

MARTIN AUSTER

Which analyst has the current lower performing score on ALXO (Alx Oncology Holdings ) with a proven track record?

ALETHIA YOUNG

Which analyst has the most public recommendations on ALXO (Alx Oncology Holdings )?

Martin Auster has 8 price targets and 5 ratings on ALXO

Which analyst is the currently most bullish on ALXO (Alx Oncology Holdings )?

Alethia Young with highest potential upside - $16.94

Which analyst is the currently most reserved on ALXO (Alx Oncology Holdings )?

Martin Auster with lowest potential downside - -$0

Alx Oncology Holdings  in the News

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company...

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025,...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?